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Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung
cancer
P Korkolopouloul, L Kaklamanis2, F Pezzella', AL Harris3 and KC Gatter'
'University Department ofCellular Science; 2Nuffield Department ofPathology and 3ICRF Oncology Laboratory, John Radcliffe
Hospital, University ofOxford, Oxford OX3 9DU, UK.
Summary Presentation of endogenous antigenic peptides to cytotoxic T lymphocytes is mediated by the
major histocompatibility complex (MHC) class I molecules. For the stable assembly of MHC class I complex
it is necessary that the antigenic peptide is transported by the MHC-encoded transporters TAP-1 and TAP-2
into a pre-Golgi region. T-cell-mediated host-vs-tumour response might therefore depend on the presence of
these molecules on tumour cells. The presence of MHC class I antigens and TAP-1 was studied in a series of
93 resection specimens of non-small-cell lung carcinomas (NSCLCs) by immunohistochemical methods using
antibodies against the assembled class I molecule, beta2-microglobulin (02-m), heavy-chain A locus, A2 allele
and TAP-1 protein. Eighty-six patients were included in the survival analysis. Total loss of class I molecule
was observed in 38% of the cases and was usually accompanied by loss of ,2-m and of heavy chain A locus.
Selective loss of A locus was seen in 8.3% and of A2 allele in 27% of the cases. TAP-1 loss was always
combined with P2-m and/or heavy chain A locus loss. No correlation was found between the expressional
status of any of the above molecules, including the selective A2 allelic loss and histological type, degree of
differentiation, tumoral stage, nodal stage and survival. Our findings suggest that loss of antigen-presenting
molecules (including both MHC class I alleles and TAP-1) is a frequent event in lung cancer. However, the
immunophenotypic profile of MHC class I and TAP-1 seems to be unrelated in vivo to the phenotype, growth
or survival of NSCLC.
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The major histocompatibility complex (MHC) comprises an
array of genes located on chromosome 6 in humans and
encodes several sets of immunoregulatory molecules-the
classical transplantation antigens (class I), the immune
response-associated antigens (class II) and complement genes
(class III) (Dausset, 1981). MHC class I molecules are
polymorphic transmembrane glycoproteins composed of two
polypeptide chains. The heavy chain (mol. wt. 4.5 kDa) is
highly polymorphic and encoded by a group of closely linked
loci, HLA-A, -B and -C. Its extracellular portion forms three
domains al, a2, a3 (each approximately 90 amino acids long),
which are coded by separate exons, while P2-m is non-
polymorphic and encoded by a different gene on chromo-
some 15. The interaction of P2-m with the o3 extracellular
domain of the heavy chain plays a crucial role in the func-
tional expression of the final product. Equally important in
the formation of functional MHC class I molecules is the
interaction of heavy-chain P2-m with the antigenic peptides
(Arce-Gomez et al., 1978; Ploegh et al., 1981; Bodmer, 1987;
Townsend et al., 1990).
MHC class I molecules are widely distributed on most
nucleated cells, with the exception of sperm, trophoblast,
neurons and hepatocytes (Daar et al., 1984). They regulate
the ability of cytotoxic T lymphocytes (CTLs) to recognise
antigens (Zinkernagel et al., 1979) whereas natural killer cell
cytotoxicity has been shown to be inversely correlated with
the degree of class I expression (Karre et al., 1986). MHC
class I molecules present predominantly endogenous antigens,
which are derived from the cytoplasmic pool and assembled
within the endoplasmic reticulum with newly synthesised
class I and P2-m (Townsend et al., 1990). These antigenic
peptides are transported by a protein complex carrier into the
pre-Golgi regions. These transporters of antigenic peptides
are heterodimers composed of the products of two genes
(TAP-I and TAP-2) located in the class II region of the
MHC. Recently it was also shown that a chaperone
molecule, calnexin, mediates heavy-chain-P2-m dimerisation
and binding of the dimers to TAP molecules facilitates their
assembly with TAP-transported peptides. (Trowsdale et al.,
1990; Kleijmeer et al., 1992; Spies et al., 1992; Ortman et al.,
1994).
There is an ever increasing body of evidence that suggests
that surface MHC class I antigen expression is altered on
human tumours, in the sense of a loss or down-regulation of
these molecules (Orgad et al., 1985; Festenstein and Garrido,
1986; Rees et al., 1988; Lopez-Nevot et al., 1989; Wintzer et
al., 1990; Goepel et al., 1991). Recently similar findings were
also described regarding the immunophenotype of TAP-1 in
cervical and colorectal tumours (Cromme et al., 1994; Kak-
lamanis et al., 1994). There have been only a few studies on
the expression of these antigens in lung cancer (Doyle, 1985;
Funa et al., 1986; Diimmrich et al., 1990; Redondo et al.,
1991a, b) and these deal mainly with alterations of P2-m and
heavy chains.
The present study was undertaken to investigate the exp-
ression of MHC class I antigens along with that of TAP-1
protein in a large series of non-small-cell lung carcinomas
(NSCLCs) and to examine its relationship with clinico-
pathological data.
Materials and methods
Patients
Ninety-three specimens from patients undergoing resection
for lung carcinomas at the John Radcliffe Hospital between
1984 and 1988 were studied. The characteristics of all
patients studied are shown in Table I. Patients had under-
gone surgery if their tumour was apparently limited to one
lobe with no evidence of metastasis and their residual lung
function was good. The pathalogical stages of the tumours
were TI and T2 and the nodal status NO and N1, according
to the TNM classification. The patients had not received
radiotherapy or chemotherapy before surgery. Survival data
were available in all cases but patients dying within the first
post-operative month or those dying of other causes were
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Table I Characteristics of 86 patients with non-small-cell lung carcinoma in which survival was studied in
relation to HLA class I and TAP-I protein expression
Non-small-cell lung Squamous cell
carcinoma carcinoma Adenocarcinoma
W6/32 TAP-i W6/32 TAP-i W6/32 TAP-I
Characteristic +/- +/_ +/- +/- +/- +/-
No. of patients 49/37 64/22 30/27 40/17 19/10 24/5
Male 36/32 50/18 22/25 33/14 14/7 17/4
Female 13/5 14/4 8/2 7/3 5/3 7/1
Mean age at surgery 60.1/ 59.7/ 61.0/ 60.5/ 59.3/ 58.2/
60.6 61.3 60.0 60.7 61.8 64.4
s.d. 7.9/8.0 8.2/7.0 8.4/7.0 7.6/6.9 7.7/10.1 8.0/4.2
F-value 1.025* 1.372* 1.440* 1.213* 1.721* 3.628*
T stage 1 20/18 27/11 13/16 20/9 7/2 7/2
T stage 2 29/19 37/11 17/11 20/8 12/8 17/3
N stage 0 35/27 43/19 24/19 29/14 11/8 14/5
N stage 1 14/10 21/3 6/8 11/3 8/2 10/0
Differentiation
Good 3/1 3/1 1/1 1/1 2/0 2/0
Moderate 19/16 25/10 10/11 14/7 9/5 11/3
Poor 27/20 36/11 19/15 25/9 8/5 11/2
*Statistically non-significant (P>0.05).
eliminated from survival analysis. There were 73 men and 20
women with a mean age of 60.3 years (s.d. 7.8, range 35-74).
Survival analysis was based on 86 patients. By the time this
study was undertaken 35 patients had died after a mean
( ± s.d.) post-operative survival of 459 ( ± 512) days. Table I
shows the characteristics of the 86 patients included in the
survival analysis according to the expressional status of
MHC class I molecules.
Tissues
Representative samples from the tumours were snap frozen
in liquid nitrogen and stored at - 70°C. Histological diag-
nosis, evaluation of the differentiation and nodal status were
assessed by light microscopy of routinely processed tissue
with histochemical and immunohistochemical confirmation
when necessary. Classification was performed according to
the WHO system (Sobin et al., 1982). Of the 93 cases
examined, 61 were squamous carcinomas (SQCs) and 32
adenocarcinomas (ACs). There were four well-differentiated,
39 moderately differentiated and 50 poorly differentiated
tumours.
Monoclonal antibodies
Immunohistochemical analysis included four monoclonal
(W6/32, BBM-1, MA2.1 and HCA2) and a polyclonal (AKI-
7) antibody. W6/32 appears to detect an antigenic deter-
minant shared along the HLA-A, B and C loci (Barnstable et
al.,1978). This determinant is a product of the interaction
between the HLA-A, B, C and. P2-m polypeptide chains
(Parham et al., 1979). BBM-1 is a specific monoclonal
antibody against P2-m (Brodsky et al., 1979). MA2.1 detects
HLA-A2 and B17 (McMichael et al., 1980) whereas HCA2
recognises an epitope unique for HLA-A locus heavy chains
that is present on the free heavy chain only (Stam et al.,
1990). For the detection of TAP-1 protein we used the
affinity purified polyclonal antibody AK1-7 raised against the
carboxy-terminal peptide of TAP-1 sequence. Two lymphop-
lasmacytoid cell lines were used as negative and positive
controls respectively for the specificity of this antibody. The
first is the mutant LCL721.174, which has deleted both the
TAP genes, and the second the wild-type LCL721. (Kelly et
al., 1992; Spies et al., 1992). This antibody was used at a
dilution 1:100. In the mutant cell line there was no
immunoreactivity with either the W6/32 or the AK1-7
antibodies implying that in the absence of the transporter
molecule there was no functional expression of the MHC
class I molecules. The wild-type cell line showed strong
cytoplasmic positivity with the AKI-7 antibody and expres-
sion of W6/32 was always detected.
Immunohistochemistry
Cryostat sections (7 mm thick) were fixed in acetone for
10 min at room temperature, left to dry overnight and stored
at - 20°C until required for staining. Immunohistochemical
staining was performed using the alkaline phosphatase-anti-
alkaline phosphatase (APAAP) method as described prev-
iously (Cordell et al., 1984). For the polyclonal antibody
AK1-7 a single modification of this technique was made,
using an incubation step of mouse-anti-rabbit immunog-
lobulin.
Assessment ofstaining
Microscopic examination of immunohistochemically stained
sections was carried out by two observers. The whole section
was screened for the distribution of HLA antigens but areas
of obvious tumour necrosis were avoided for counting. Nor-
mal respiratory epithelium and inflammatory lymphoid cells
were used in each case as a control. Thus, a particular
antigen was only considered to be lost by the tumour if it
was still expressed by the adjacent normal respiratory
epithelium and the lymphocytes. The evaluation was semi-
quantitative. A tumour was scored as negative (-) if less
than 10% of the cells were labelled and as positive (+) if
more than 75% of the cells were strongly stained. When the
percentage of positive neoplastic cells was between 10% and
75% irrespective of the staining intensity the tumour was
recorded as showing reduced expression.
Statistical analysis
The association between HLA expression and tumour type,
degree of differentiation, T stage and N stage was inves-
tigated by the use of frequency tables (Altman, 1991). Sur-
vival was measured in days from the date of surgery.
Actuarial survival curves were plotted using the Kap-
lan-Meier method (Kaplan and Meier, 1958). The statistical
significance was calculated using the log-rank test (Peto et al.,
1977) and the hazard ratio with a 95% confidence interval
was calculated as described by Machin and Gardner (1989).
The homogeneity of age in the various subgroups was
assessed by calculating the F-value with one-way analysis of
variances (Armitage and Berry, 1987).
Results
Tables I and II summarise the results of the immunohis-
tochemical expression of HLA class I and TAP-1 in the
groups of SQC and AC.Loss of antigen-presenting molecules in lung cancer
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Table II Survival of 86 patients with non-small-cell lung carcinoma according to MHC
class I and TAP-1 protein expression
Results of No. of 5 year Hazard ratio
staining patients survival (%) X-square P-value (95% CI)
W6/32 positive 49 56.6
0.0001 >0.95 0.99 (0.5-1.96)
W6/32 negative 37 55
W6/32 positive
MA2.1 positive 30 57.6
0.2839 >0.5 0.75 (0.26-2.16)
W6/32 positive
MA2.1 negative 13 53.9
AK1-7 positive 64 54.7
0.1773 >0.5 1.18 (0.55-2.5)
AK1-7 negative 22 56.3
Figure 1 (a) W6/32 expression in a squamous cell carcinoma (bar 100 mm). (b) MA2.1 selective loss from the same case (bar
50 mm). (c) Loss of W6/32 in an adenocarcinoma (bar 100mm). (d) Expression of TAP-I in the above case (bar 100 mm).
Lymphocytes and stromal cells are positive in all the cases shown above.
HLA class I and TAP-I expression
In the normal lung class I antigens, TAP-1, HCA2, BBM.1
and MA2.1 were expressed by the endothelial cells, lym-
phocytes, bronchiolar and alveolar epithelium and alveolar
macrophages. As far as the tumours are concerned, 37 out of
93 cases showed loss of the framework antigenic determinant,
either partial or complete, evidenced by reduced (five cases)
or negative (32 cases) staining with W6/32 antibody. The loss
was commoner in SQC (27 out of 61 cases) than in AC (10
out of 32 cases), although no statistically significant
difference could be reached. Loss of the framework antibody
W6/32 was usually accompanied by loss ofP2-m (28 out of 37
cases) and loss of A locus (19 out of 37 cases). Selective loss
of A locus was detected in 2 out of 24 cases positive with
W6/32. Selective loss of A2 allele was seen in 13 out of 43
cases in which A2 was present in the adjacent lung. All 13
cases were positive for W6/32.
TAP-I protein was lost in 22 cases (17 SQC and 5AC).
These cases also showed synchronous loss of P2-m and/or
heavy chain. A locus-isolated TAP-1 defect was not identified
in our series. All cases showing loss of TAP-I molecule were
negative for W6/32 as well. No relationship could be found
between the mode of MHC class I antigen and TAP-1 exp-
ression on the one hand and histological type, degree of
differentiation, tumoral or nodal stage on the other, even
when the last three parameters were examined with each
histological group separately (Figure 1).
Survival analysis
The results of the survival analysis on the series of 86 non-
small-cell lung carcinoma according to the staining with the
antibodies W6/32, TAP-1 and MA 2.1 are summarised in
Table II and the survival curves are shown in Figure 2a, b
and c. Furthermore we examined whether the selective loss of
the A2 allele was of any prognostic value: for this purpose
we compared the survival of patients with W6/32- and
MA2.1- positive tumours with that of patients with W6/2-
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Figure 2 Survival in relation to loss of expression of TAP-1 (a),
MA2.1 (b) and W6/32 (c).
positive and MA2. 1- reduced or -negative tumours. No
difference emerged. The distribution of ages was
homogeneous across all subgroups ofpatients when analysed,
independently of the expressional status of MHC class 1 and
TAP-1 molecules (Table II). There was no association of
staining with any of these antibodies with tumour
differentiation, T stage or N stage (data not shown). Survival
curves were plotted also for the other two antibodies, BBM1
and HCA2, but no difference could be found (data not
shown). No difference could be detected even when the
groups of squamous cell and adenocarcinoma were examined
separately (Figure 3).
Discussion
In the present study we detected two types of alterations in
the surface expression of MHC class I antigens by the neop-
lastic cells: total loss of MHC class I molecule and selective
losses of HLA-A locus and A2 allele. Total loss of MHC
class I molecule as evidenced by negative reaction to W6/32
Figure 3 Survival in relation to loss of expression W6/32 in (a)
squamous cell carcinomas and (b) adenocarcinomas.
was detected in 38% of our cases, a figure higher than those
quoted in previous studies (Redondo et al., 1991a, b). Selec-
tive losses of A locus and A2 allele were identified in 8.3%
and 27% respectively. Our findings show that loss of the
assembled molecule is not only due to loss of P2-m but also
to loss of TAPI molecules and/or heavy chains.
Previous studies of lung cancer have shown no difference
between P2-m and heavy chain expression (Doyle, 1985;
Redondo et al., 1991b). However, in our series we have seen
such a difference in a small proportion of cases (9.1%). Such
uncoordinated expression of 12-m and heavy chains has also
been observed in colon carcinomas (Momburg et al., 1989).
It is also worthy of note that the failure to detect A locus or
A2 allele is not necessarily associated with loss of the
assembled class I molecule. This is similar to the situation in
colon carcinomas (Rees et al., 1988; Kaklamanis et al., 1992).
Interestingly, loss of the transporter protein was always
combined with P2-m and/or A locus loss and was invariably
associated with lack of expression of the assembled class I
molecule. This implies that in the absence of the transporter
protein the antigenic peptide is not able to join the MHC
class I molecule rendering the assembly of the heavy chains
and P2-m impossible.
The mechanisms by which total or partial losses of HLA
antigens occur are not yet well known. Theoretically, they
might reflect underlying chromosomal abnormalities (e.g.
translocations or deletions) in the short arm of chromosome
6 for the heavy chains and TAP-I or chromosome 15 for
P2-m. However, there is no current evidence to support this.
In fact, molecular studies in lung carcinomas have failed to
demonstrate rearrangements of class I genes in cases with
abnormal surface expression of these antigens (Doyle et al.,
1985; Redondo et al., 1991a). A more plausible mechanism is
that of transcriptional down-regulation of MHC class I
genes, which could be related to the action of cellular
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oncogene products, such as c-myc oncoprotein. This has been
shown to operate in SLCL tumours and cell lines (Doyle,
1985). However, in NSCLC expression of class I antigens
appears to be independent ofc-myc expression. Alternatively,
it has been hypothesised that a post-transcriptional mechan-
ism may be involved in the differential expression of HLA-A,
B, C products in NSCLC, since there is not always a close
relation between the surface expression of these antigens and
their mRNAs (Redondo et al., 1991a). Moreover, e-
interferon-mediated regulation of HLA-gene subsets has been
documented (Haken et al., 1989; Schmidt et al., 1990).
The lack of association between MHC class I loss and
degree of differentiation, in our study, is at variance with
data from the literature relating a loss of these antigens in
lung cancer to the degree of differentiation as well as to the
presence of aneuploidy in NSCLC and to an increased
mitotic rate (Dammrich et al., 1990; Redondo et al., 1991b).
Based upon these findings it has been suggested that MHC
class I loss is an indication of a more aggressive phenoptype
and of a more rapid tumour growth. However, no relation-
ship with the tumoral or nodal stage was found in the studies
of Dammrich et al. (1990) and Redondo et al. (1991b), in
concordance with the results of the present study.
Experiments in murine models have shown that the loss of
MHC class I antigen expression allows tumour growth and
metastasis formation by escape from T-cell-mediated surveil-
lance (Hui et al., 1984; Tanaka et al., 1985; Wallich et al.,
1985). Following this line of argument it was tempting to
speculate that tumours lacking the above antigens would be
prone to pursue a more unfavourable clinical course as com-
pared with those with normal expression. This idea was
further strengthened by the association of MHC class I loss
with a poorer degree of differentiation as reported for breast
(Wintzer et al., 1990), colon (Momburg et al., 1986) and
laryngeal (Lopez-Nevot et al., 1989) carcinomas. Clinical
studies however have failed to confirm this idea, at least as
far as colorectal carcinomas are concerned (Stein et al., 1988;
M6ller et al., 1991). In the case of breast cancer, however,
the question of prognostic relevancy of MHC class I expres-
sion is still open (Wintzer et al., 1990; Concha et al., 1991).
This study shows that down-regulation of antigen-
presenting and antigen-transporting molecules is a common
phenomenon in NSCLC. Specific allelic loss (A2) was also
frequently detected and it might be of interest to study the
expression of the entire allelic repertoire present on tumour
cells. Although no correlation was found with chnico-
pathological parameters, the understanding of the underlying
mechanisms that are responsible for this defective expression,
would be of paramount importance.
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